Off-label prescribing is the prescription of a registered medicine for a use that is not included in the product information. The practice is common, with rates up to 40% in adults and up to 90% in paediatric patients.
Off-label prescribing is not illegal and may sometimes be clinically appropriate, but is associated with a number of clinical, safety and ethical issues. To date, no explicit guidance has been available to help clinicians assess appropriateness in off-label prescribing.
We describe the development of a guide for clinicians, policymakers and funders of health care in evaluating the appropriateness of medicines proposed for off-label use.
Three broad categories of appropriate off-label use are identified:
An appropriate process for informed consent is proposed for each category.
If there is no high-quality evidence supporting off-label use, and the medicine is not suitable for exceptional or research indications, its use is generally not recommended. This will reduce inappropriate use, enhance patient safety by reducing exposure to unnecessary risk, and may stimulate more clinically relevant medicines research.
- 1. Turner S. Unregistered and off-label drug use in paediatric inpatients. Aust J Hosp Pharm 1999; 29: 265-268.
- 2. Rayburn W, Farmer K. Off-label prescribing during pregnancy. Obstet Gynecol Clin North Am 1997; 24: 471-479.
- 3. Laetz T, Silberman G. Reimbursement policies constrain the practice of oncology. JAMA 1991; 266: 2996-2999.
- 4. Brosgart C, Mitchell T, Charlebois E, et al. Off-label drug use in human immunodeficiency virus disease. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12: 56-62.
- 5. Douglas-Hall P, Fuller A, Gill-Banham S. An analysis of off-licence prescribing in psychiatric medicine. Pharm J 2001; 267: 890-891.
- 6. McIntyre J, Conroy S, Avery A, et al. Unlicensed and off label prescribing of drugs in general practice. Arch Dis Child 2000; 83: 498-501.
- 7. Pandolfini C, Impicciatore P, Provasi D, et al. Off-label use of drugs in Italy: a prospective, observational and multicentre study. Acta Paediatr 2002; 91: 339-347.
- 8. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off-label drug use in paediatric wards in European countries. BMJ 2000; 320: 79-82.
- 9. Cuzzolin L, Zaccaron A, Fanos V. Unlicensed and off-label uses of drugs in paediatrics: a review of the literature. Fundam Clin Pharmacol 2003; 17: 125-131.
- 10. Stephenson T. Medicines for children — the last century and the next. Arch Dis Child 2001; 85: 177-179.
- 11. Cohen JS. Dose discrepancies between the physician’s desk reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events. Arch Intern Med 2001; 161: 957-964.
- 12. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006; 166: 1021-1026.
- 13. Blum R. Legal consideration in off-label medication prescribing. Arch Intern Med 2002; 162: 1777-1779.
- 14. Kelly M, Gazarian M, McPhee J. Off-label prescribing [letter]. Aust Prescr 2005; 28: 7.
- 15. Collier J. Paediatric prescribing: using unlicensed drugs and medicines outside their licensed indications. Br J Clin Pharmacol 1999; 48: 5-8.
- 16. Gazarian M. Why are children still therapeutic orphans? [editorial]. Aust Prescr 2003; 26: 122-123.
- 17. American Academy of Pediatrics, Committee on Drugs. Uses of drugs not described in the package insert (off-label uses). Pediatrics 2002; 110: 181-183.
- 18. Neubert A, Dormann H, Weiss J, et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf 2004; 27: 1059-1067.
- 19. European Medicines Agency (EMEA). Evidence of harm from off label or unlicensed medicines in children, London: EMEA, October 2004 (EMEA/11207/04). http://www.emea.eu.int/pdfs/human/peg/1120704en.pdf (accessed Oct 2006).
- 20. Roberts R, Rodriguez W, Murphy D, Crescenzi T. Pediatric drug labelling. Improving the safety and efficacy of pediatric therapies. JAMA 2003; 290: 905-911.
- 21. Schreiner M. Paediatric clinical trials: redressing the imbalance. Nat Rev Drug Discov 2003; 2: 949-961.
- 22. Tan E, Stewart K, Pearce C, et al. Understanding off-label and unlicensed prescribing: combining qualitative and quantitive methodologies. Clin Exp Pharmacol Physiol 2004; 31 Suppl 1: A84.
- 23. Ekins-Daukes S, Helms P, Taylor M, McLay J. Off-label prescribing to children: attitudes and experience of general practitioners. Br J Clin Pharmacol 2005; 60: 145-149.
- 24. European Parliament. Committee on the Environment, Public Health and Food Safety. Draft recommendation for second reading on the Council common position for adopting a regulation of the European Parliament and of the Council on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. http://www.europarl.europa.eu/meetdocs/2004_2009/documents/pr/605/605939/605939en.pdf (accessed Oct 2006).
- 25. NSW Department of Health. Annual report (2002–03). Sydney: NSW Health, 2003: 210.
- 26. Guyatt G, Sackett D, Cook D. How to use an article about therapy or prevention. A. Are the results of the study valid? JAMA 1993; 270: 2598-2601.
- 27. Guyatt G, Sackett D, Cook D. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? JAMA 1994; 271: 59-63.
- 28. Levine M, Walter S, Lee H, et al. How to use an article about harm. JAMA 1994; 271: 1615-1619.
- 29. Oxman A, Cook D, Guyatt G. VI. How to use an overview. JAMA 1994; 272: 1367-1371.
- 30. National Health and Medical Research Council. How to use the evidence: assessment and application of scientific evidence. Handbook series on preparing clinical practice guidelines. Canberra: NHMRC, 2000.
- 31. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001; 323: 334-336.
- 32. Dans AL, Dans LF, Guyatt GH, Richardson S. How to decide on the applicability of clinical trial results to your patient. JAMA 1998; 279: 545-549.
- 33. Craig JC, Irwig LM, Stockler MR. Evidence-based medicine: useful tools for decision making. Med J Aust 2001; 174: 248-253. <MJA full text>
- 34. Ferner R, McDowell S. How NICE may be outflanked. BMJ 2006; 332: 1268-1271.
- 35. Schirm E, Tobi H, de Jong-van den Berg LTW. Risk factors for unlicensed and off-label drug use in children outside the hospital. Pediatrics 2003; 111: 291-295.
- 36. McAlister F, Strauss S, Guyatt G, Haynes R. Integrating research evidence with the care of the individual patient. JAMA 2000; 283: 2829-2836.
- 37. Hyrich K, Silman A, Watson K, Symmons D. Anti-tumour necrosis factor therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 2004; 63: 1538-1543.
- 38. Weinstein A, Marlowe S, Korn J, Farouhar F. Low-dose methotrexate treatment of rheumatoid arthritis. Am J Med 1985; 79: 331-337.
- 39. Stevens MCG, Mahler H, Parkes S. The health status of adult survivors of cancer in childhood. Eur J Cancer 1998; 34: 694-698.
- 40. Guyatt G, Sinclair J, Cook D, et al. How to use a treatment recommendation. JAMA 1999; 281: 1836-1843.
- 41. Steinman MA, Bero LA, Chren M-M, Landefeld CS. The promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med 2006; 145: 284-293.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.